In vitro and in vivo characterization of 177Lu-huA33. A radioimmunoconjugate against colorectal cancer

Nuclear Medicine and Biology

Volumn 33, Issue 8, 2006, Pages 991-998

  Almqvist, Ylva ^a   Steffen, Ann Charlott ^a   Tolmachev, Vladimir ^a   Divgi, Chaitanya R ^b   Sundin, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

177Lu; A33 antigen; Antibody; Colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; HUMANIZED MONOCLONAL ANTIBODY A33 CYCLOHEXYLDIETHYLENETRIAMINEPENTAACETIC ACID LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA RADIATION; CANCER CELL; CANCER GRAFT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG STABILITY; FEMALE; HUMANS; IMMUNOCONJUGATES; LUTETIUM; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TISSUE DISTRIBUTION;

EID: 33751233510     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.09.003     Document Type: Article

References (37)

1. Choti M.A., Sitzmann J.V., Tiburi M.F., Sumetchotimetha W., Rangsin R., Schulick R.D., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235 (2002) 759-766
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
3. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
4. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
5. Pfister D.G., Benson III A.B., and Somerfield M.R. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 350 (2004) 2375-2382
6. Meyerhardt J.A., and Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med 352 (2005) 476-487
7. Ohlsson B., and Pålsson B. Follow-up after colorectal cancer surgery. Acta Oncol 42 (2003) 816-826
8. Shaw I.M., Rees M., Welsh F.K., Bygrave S., and John T.G. Repeat hepatic resection for recurrent colorectal liver metastases is associated with favourable long-term survival. Br J Surg 93 (2006) 457-464
9. Pessaux P., Lermite E., Brehant O., Tuech J.J., Lorimier G., and Arnaud J.P. Repeat hepatectomy for recurrent colorectal liver metastases. J Surg Oncol 93 (2006) 1-7
10. Wei A.C., Greig P.D., Grant D., Taylor B., Langer B., and Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol (2006) 668-676
11. Sutherland L.M., Williams J.A., Padbury R.T., Gotley D.C., Stokes B., and Maddern G.J. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 141 (2006) 181-190
12. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 43 (2002) 693-713
13. Liersch T., Meller J., Kulle B., Behr T.M., Markus P., Langer C., et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 23 (2005) 6763-6770
14. Behr T.M., Liersch T., Greiner-Bechert L., Griesinger F., Behe M., Markus P.M., et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94 (2002) 1373-1381
15. Heath J.K., White S.J., Johnstone C.N., Catimel B., Simpson R.J., Moritz R.L., et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 94 (1997) 469-474
16. Johnstone C.N., Tebbutt N.C., Abud H.E., White S.J., Stenvers K.L., Hall N.E., et al. Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 279 (2000) G500-G510
17. Bazzoni G. The JAM family of junctional adhesion molecules. Curr Opin Cell Biol 15 (2003) 525-530
18. Garin-Chesa P., Sakamoto J., Welt S., Real F.X., Rettig W.J., and Old L.J. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol 9 (1996) 465-471
19. Welt S., Scott A.M., Divgi C.R., Kemeny N.E., Finn R.D., Daghighian F., et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 14 (1996) 1787-1797
20. Scott A.M., Lee F.T., Jones R., Hopkins W., MacGregor D., Cebon J.S., et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11 (2005) 4810-4817
21. Almqvist Y., Orlova A., Sjostrom A., Jensen H.J., Lundqvist H., Sundin A., et al. In vitro characterization of 211 At-labeled antibody A33-a potential therapeutic agent against metastatic colorectal carcinoma. Cancer Biother Radiopharm 20 (2005) 514-523
22. Lewis M.R., Zhang J., Jia F., Owen N.K., Cutler C.S., Embree M.F., et al. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol 31 (2004) 213-223
23. Kaminski M.S., Zelenetz A.D., Press O.W., Saleh M., Leonard J., Fehrenbacher L., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
24. Welt S., Divgi C.R., Kemeny N., Finn R.D., Scott A.M., Graham M., et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 12 (1994) 1561-1571
25. Moritz R.L., Ritter G., Catimel B., Cohen L.S., Welt S., Old L.J., et al. Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium. J Chromatogr A 798 (1998) 91-101
26. Chong G., Lee F.T., Hopkins W., Tebbutt N., Cebon J.S., Mountain A.J., et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 11 (2005) 4818-4826
27. de Jong M., Breeman W.A., Valkema R., Bernard B.F., and Krenning E.P. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 46 Suppl 1 (2005) 13S-17S
28. King D.J., Antoniw P., Owens R.J., Adair J.R., Haines A.M., Farnsworth A.P., et al. Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer 72 (1995) 1364-1372
29. Kwekkeboom D.J., Teunissen J.J., Bakker W.H., Kooij P.P., de Herder W.W., Feelders R.A., et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23 (2005) 2754-2762
30. Harris W.R., Yang B., Abdollahi S., and Hamada Y. Steric restrictions on the binding of large metal ions to serum transferrin. J Inorg Biochem 76 (1999) 231-242
31. Lee F.T., Mountain A.J., Kelly M.P., Hall C., Rigopoulos A., Johns T.G., et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A″-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res 11 (2005) 7080s-7086s
32. Brouwers A.H., van Eerd J.E., Frielink C., Oosterwijk E., Oyen W.J., Corstens F.H., et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45 (2004) 327-337
33. Postema E.J., Frielink C., Oyen W.J., Raemaekers J.M., Goldenberg D.M., Corstens F.H., et al. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 18 (2003) 525-533
34. Persson M., Tolmachev V., Andersson K., Gedda L., Sandstrom M., and Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 32 (2005) 1457-1462
35. Milenic D.E., Garmestani K., Chappell L.L., Dadachova E., Yordanov A., Ma D., et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29 (2002) 431-442
36. Alvarez R.D., Partridge E.E., Khazaeli M.B., Plott G., Austin M., Kilgore L., et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65 (1997) 94-101
37. Bander N.H., Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S., and Goldsmith S.J. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23 (2005) 4591-4601